Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression

Cyndi R. Morales, Dan L. Li, Zully Pedrozo, Herman I. May, Nan Jiang, Viktoriia Kyrychenko, Geoffrey W. Cho, Soo Young Kim, Zhao Wang, David Rotter, Beverly A Rothermel, Jay W Schneider, Sergio Lavandero, Thomas G. Gillette, Joseph A Hill

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Altering chromatin structure through histone posttranslational modifications has emerged as a key driver of transcriptional responses in cells. Modulation of these transcriptional responses by pharmacological inhibition of class I histone deacetylases (HDACs), a group of chromatin remodeling enzymes, has been successful in blocking the growth of some cancer cell types. These inhibitors also attenuate the pathogenesis of pathological cardiac remodeling by blunting and even reversing pathological hypertrophy. The mechanistic target of rapamycin (mTOR) is a critical sensor and regulator of cell growth that, as part of mTOR complex 1 (mTORC1), drives changes in protein synthesis and metabolism in both pathological and physiological hypertrophy. We demonstrated through pharmacological and genetic methods that inhibition of class I HDACs suppressed pathological cardiac hypertrophy through inhibition of mTOR activity. Mice genetically silenced for HDAC1 and HDAC2 had a reduced hypertrophic response to thoracic aortic constriction (TAC) and showed reduced mTOR activity. We determined that the abundance of tuberous sclerosis complex 2 (TSC2), an mTOR inhibitor, was increased through a transcriptional mechanism in cardiomyocytes when class IHDACs were inhibited. In neonatal rat cardiomyocytes, loss of TSC2 abolished HDAC-dependent inhibition of mTOR activity, and increased expression of TSC2 was sufficient to reduce hypertrophy in response to phenylephrine. These findings point to mTOR and TSC2-dependent control of mTOR as critical components of the mechanism by which HDAC inhibitors blunt pathological cardiac growth. These results also suggest a strategy to modulate mTOR activity and facilitate the translational exploitation of HDAC inhibitors in heart disease.

Original languageEnglish (US)
Article numberra34
JournalScience Signaling
Volume9
Issue number422
DOIs
StatePublished - Apr 5 2016

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Fingerprint Dive into the research topics of 'Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression'. Together they form a unique fingerprint.

  • Cite this

    Morales, C. R., Li, D. L., Pedrozo, Z., May, H. I., Jiang, N., Kyrychenko, V., Cho, G. W., Kim, S. Y., Wang, Z., Rotter, D., Rothermel, B. A., Schneider, J. W., Lavandero, S., Gillette, T. G., & Hill, J. A. (2016). Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression. Science Signaling, 9(422), [ra34]. https://doi.org/10.1126/scisignal.aad5736